Z-score Mapping for Standardized Analysis and Reporting of Cardiovascular Magnetic Resonance Modified Look-Locker Inversion Recovery (MOLLI) T1 Data: Normal Behavior and Validation in Patients with Amyloidosis
Overview
Radiology
Authors
Affiliations
Background: T1 mapping using modified Look-Locker inversion recovery (MOLLI) provides quantitative information on myocardial tissue composition. T1 results differ between sites due to variations in hardware and software equipment, limiting the comparability of results. The aim was to test if Z-scores can be used to compare the results of MOLLI T1 mapping from different cardiovascular magnetic resonance (CMR) platforms.
Methods: First, healthy subjects (n = 15) underwent 11 combinations of native short-axis T1 mapping (four CMR systems from two manufacturers at 1.5 T and 3 T, three MOLLI schemes). Mean and standard deviation (SD) of septal myocardial T1 were derived for each combination. T1 maps were transformed into Z-score maps based on mean and SD values using a prototype post-processing module. Second, Z-score mapping was applied to a validation sample of patients with cardiac amyloidosis at 1.5 T (n = 25) or 3 T (n = 13).
Results: In conventional T1 analysis, results were confounded by variations in field strength, MOLLI scheme, and manufacturer-specific system characteristics. Z-score-based analysis yielded consistent results without significant differences between any two of the combinations in part 1 of the study. In the validation sample, Z-score mapping differentiated between patients with cardiac amyloidosis and healthy subjects with the same diagnostic accuracy as standard T1 analysis regardless of field strength.
Conclusions: T1 analysis based on Z-score mapping provides consistent results without significant differences due to field strengths, CMR systems, or MOLLI variants, and detects cardiac amyloidosis with the same diagnostic accuracy as conventional T1 analysis. Z-score mapping provides a means to compare native T1 results acquired with MOLLI across different CMR platforms.
Duenweg S, Bobholz S, Lowman A, Winiarz A, Nath B, Barrett M Front Oncol. 2025; 15:1433444.
PMID: 39990680 PMC: 11842255. DOI: 10.3389/fonc.2025.1433444.
Thahakoya R, Roach K, Han M, Bhattacharjee R, Jiang F, Luitjens J Osteoarthr Cartil Open. 2024; 6(4):100538.
PMID: 39554476 PMC: 11566348. DOI: 10.1016/j.ocarto.2024.100538.
Novel Magnetic Resonance Imaging Tools for Hypertrophic Cardiomyopathy Risk Stratification.
Alajmi F, Kang M, Dundas J, Haenel A, Parker J, Blanke P Life (Basel). 2024; 14(2).
PMID: 38398708 PMC: 10889913. DOI: 10.3390/life14020200.
Inter-scanner comparability of Z-scores for native myocardial T1 and T2 mapping.
Razzaq S, Haririsanati L, Eyre K, Garg R, Chetrit M, Friedrich M J Cardiovasc Magn Reson. 2024; 26(1):100004.
PMID: 38211657 PMC: 11211228. DOI: 10.1016/j.jocmr.2023.100004.
Groschel J, Trauzeddel R, Muller M, von Knobelsdorff-Brenkenhoff F, Viezzer D, Hadler T J Cardiovasc Magn Reson. 2023; 25(1):47.
PMID: 37574535 PMC: 10424349. DOI: 10.1186/s12968-023-00954-9.